Advancing the potential of peptide-PMO compounds in exon skipping therapy for DMD

Slični predmeti

• Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment.
  od: Betts, C, i dr.
  Izdano: (2012)
• Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment
  od: Betts, C, i dr.
  Izdano: (2018)
• Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy
  od: Blain, A, i dr.
  Izdano: (2018)
• Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy.
  od: Alison M Blain, i dr.
  Izdano: (2018-01-01)
• Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts.
  od: Joshua Lee, i dr.
  Izdano: (2018-01-01)